To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrineresponsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves diseasefree survival for postmenopausal women with endocrineresponsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high. © Springer Science+Business Media, LLC. 2008. [International Breast Cancer Study Group (IBCSG) ]

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93 / O. Pagani, S.G.. - In: BREAST CANCER RESEARCH AND TREATMENT. - ISSN 0167-6806. - 116:3(2009 Aug), pp. 491-500. [10.1007/s10549-008-0225-9]

Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93

M. Colleoni
Membro del Collaboration Group
;
A. Veronesi
Membro del Collaboration Group
;
M. Castiglione
Membro del Collaboration Group
;
G. Viale
Membro del Collaboration Group
;
L. Orlando
Membro del Collaboration Group
;
S. Dellapasqua
Membro del Collaboration Group
;
G. Curigliano
Membro del Collaboration Group
;
F. De Braud
Membro del Collaboration Group
;
R. Orecchia
Membro del Collaboration Group
;
A. Costa
Membro del Collaboration Group
;
S. Zurrida
Membro del Collaboration Group
;
P. Veronesi
Membro del Collaboration Group
;
V. Sacchini
Membro del Collaboration Group
;
P. Rey
Membro del Collaboration Group
;
M. Forni
Membro del Collaboration Group
;
A. Schindler
Membro del Collaboration Group
;
2009

Abstract

To compare the efficacy of chemoendocrine treatment with that of endocrine treatment (ET) alone for postmenopausal women with highly endocrine responsive breast cancer. In the International Breast Cancer Study Group (IBCSG) Trials VII and 12-93, postmenopausal women with node-positive, estrogen receptor (ER)-positive or ER-negative, operable breast cancer were randomized to receive either chemotherapy or endocrine therapy or combined chemoendocrine treatment. Results were analyzed overall in the cohort of 893 patients with endocrineresponsive disease, and according to prospectively defined categories of ER, age and nodal status. STEPP analyses assessed chemotherapy effect. The median follow-up was 13 years. Adding chemotherapy reduced the relative risk of a disease-free survival event by 19% (P = 0.02) compared with ET alone. STEPP analyses showed little effect of chemotherapy for tumors with high levels of ER expression (P = 0.07), or for the cohort with one positive node (P = 0.03). Chemotherapy significantly improves diseasefree survival for postmenopausal women with endocrineresponsive breast cancer, but the magnitude of the effect is substantially attenuated if ER levels are high. © Springer Science+Business Media, LLC. 2008. [International Breast Cancer Study Group (IBCSG) ]
Breast cancer; Chemoendocrine therapy; Estrogen receptors; Postmenopausal;
Settore MEDS-09/A - Oncologia medica
ago-2009
25-ott-2008
Article (author)
File in questo prodotto:
File Dimensione Formato  
s10549-008-0225-9.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Licenza: Nessuna licenza
Dimensione 281.05 kB
Formato Adobe PDF
281.05 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1252984
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 31
  • ???jsp.display-item.citation.isi??? 30
  • OpenAlex ND
social impact